While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses, …

With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines,
functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-…

In the absence of effective vaccines and with limited therapeutic options, convalescent plasma
is being collected across the globe for potential transfusion to coronavirus disease 2019 (…

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19
pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in …

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants
have recently emerged, becoming the dominant circulating strains in many countries. …

The standard dosing of the Pfizer/BioNTech BNT162b2 mRNA vaccine validated in clinical
trials includes two doses administered three weeks apart. While the decision by some public …

Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-…

Spacing of BNT162b2 mRNA doses beyond 3 weeks raises concerns about vaccine efficacy.
We longitudinally analyze B cell, T cell, and humoral responses to two BNT162b2 mRNA …

While an important part of the world’s population is vaccinated against SARS-CoV-2, new
variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent …